Altering the course of schizophrenia: progress and perspectives

被引：294

作者：

Millan, Mark J. ^{[1
]}

Andrieux, Annie ^{[2
]}

Bartzokis, George ^{[3
]}

Cadenhead, Kristin ^{[4
]}

Dazzan, Paola ^{[5
]}

Fusar-Poli, Paolo ^{[5
]}

Gallinat, Juergen ^{[6
]}

Giedd, Jay ^{[4
]}

Grayson, Dennis R. ^{[7
]}

Heinrichs, Markus ^{[8
]}

Kahn, Rene ^{[9
]}

Krebs, Marie-Odile ^{[10
]}

Leboyer, Marion ^{[11
]}

Lewis, David ^{[12
]}

Marin, Oscar ^{[13
]}

Marin, Philippe ^{[14
]}

Meyer-Lindenberg, Andreas ^{[15
]}

McGorry, Patrick ^{[16
]}

McGuire, Philip ^{[17
]}

Owen, Michael J. ^{[18
]}

Patterson, Paul ^{[19
]}

Sawa, Akira ^{[20
,21
]}

Spedding, Michael ^{[22
]}

Uhlhaas, Peter ^{[19
]}

Vaccarino, Flora ^{[23
]}

Wahlestedt, Claes ^{[24
]}

Weinberger, Daniel ^{[25
]}

机构：

[1] Inst Rech IDR Servier, Croissy Sur Seine, France

[2] Grenoble Inst Neurosci, Grenoble, France

[3] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA

[4] Univ Calif San Diego, La Jolla, CA 92093 USA

[5] Kings Coll London, Inst Psychiat Psychol & Neurosci, London WC2R 2LS, England

[6] Charite St Hedwig Krankenhaus, Psychiat Univ Klin, Berlin, Germany

[7] Univ Illinois, Chicago, IL USA

[8] Freiburg Brain Imaging Ctr, Freiburg, Germany

[9] Brain Ctr Rudolf Magnus, Utrecht, Netherlands

[10] Ctr Hosp St Anne, Paris, France

[11] Psychopathol & Genet Malad Psychiat, Paris, France

[12] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA

[13] MRC, Ctr Dev Neurobiol, London, England

[14] CNRS, Montpellier, France

[15] Cent Inst Mental Hlth, Mannheim, Germany

[16] Natl Ctr Excellence Youth Mental Hlth, Parkville, Vic, Australia

[17] Kings Coll London, Inst Psychiat, London WC2R 2LS, England

[18] MRC, Ctr Neuropsychiat Genet & Genom, Cardiff, S Glam, Wales

[19] Inst Neurosci & Psychol, Glasgow, Lanark, Scotland

[20] Johns Hopkins Univ, Sch Med, Baltimore, MD USA

[21] Johns Hopkins Univ, Sch Publ Hlth, Baltimore, MD USA

[22] Spedding Res Solut SARL, Le Vesinet, France

[23] Yale Univ, Sch Med, New Haven, CT 06520 USA

[24] Univ Miami, Miller Sch Med, Miami, FL 33136 USA

[25] Lieber Inst Brain Dev, Baltimore, MD USA

来源：

NATURE REVIEWS DRUG DISCOVERY | 2016年 / 15卷 / 07期

关键词：

ULTRA-HIGH-RISK; RANDOMIZED CONTROLLED-TRIAL; CLINICAL HIGH-RISK; POLYUNSATURATED FATTY-ACIDS; PRENATAL IMMUNE ACTIVATION; PREVENTS ADULT DEFICITS; ADD-ON TREATMENT; 1ST-EPISODE PSYCHOSIS; YOUNG-PEOPLE; PREFRONTAL CORTEX;

D O I：

10.1038/nrd.2016.28

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Despite a lack of recent progress in the treatment of schizophrenia, our understanding of its genetic and environmental causes has considerably improved, and their relationship to aberrant patterns of neurodevelopment has become clearer. This raises the possibility that 'disease-modifying' strategies could alter the course to - and of - this debilitating disorder, rather than simply alleviating symptoms. A promising window for course-altering intervention is around the time of the first episode of psychosis, especially in young people at risk of transition to schizophrenia. Indeed, studies performed in both individuals at risk of developing schizophrenia and rodent models for schizophrenia suggest that pre-diagnostic pharmacotherapy and psychosocial or cognitive-behavioural interventions can delay or moderate the emergence of psychosis. Of particular interest are 'hybrid' strategies that both relieve presenting symptoms and reduce the risk of transition to schizophrenia or another psychiatric disorder. This Review aims to provide a broad-based consideration of the challenges and opportunities inherent in efforts to alter the course of schizophrenia.

引用

页码：485 / 515

页数：31

共 315 条

[1] Pharmacotherapy challenges in patients with first-episode psychosis [J].